New shot aims to shield heart attack survivors from future crises
NCT ID NCT07290699
Summary
This study is testing if adding a new injectable cholesterol-lowering drug (recaticimab) to standard treatment right after a heart attack is more effective. It will involve over 2,400 recent heart attack patients. The goal is to see if this early, intensive approach better controls cholesterol, reduces inflammation, and prevents future major heart problems like another heart attack or stroke over one year.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STEMI - ST ELEVATION MYOCARDIAL INFARCTION are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.